Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

John Halwig

Allergy Austell, GA Medical Doctor

NPI 1841230760 CMS profile 129367

1620 Mulkey Rd, Ste 100, Austell, GA 30106

Open in the dashboard

General payments

$4,948

221 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, John Halwig of Austell, GA is reported in the CMS Open Payments database as having received $4,948 across 221 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $1,466 65
2021 General $1,169 54
2020 General $1,269 48
2019 General $1,043 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Halwig
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to John Halwig were reported at $0. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year John Halwig Allergy median Middle half National median
2019 $1,043 $506 $151–$1,337 $163
2020 $1,269 $409 $108–$1,162 $114
2021 $1,169 $549 $125–$1,485 $132
2022 $1,466 $666 $161–$1,594 $149
2023 $0 $780 $186–$1,916 $160
2024 $0 $1,031 $271–$2,196 $164
2025 $0 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Octapharma USA, Inc. $812 13 payments
  2. Regeneron Healthcare Solutions, Inc. $682 28 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $576 22 payments
  4. GlaxoSmithKline, LLC. $463 34 payments
  5. AstraZeneca Pharmaceuticals LP $415 21 payments
  6. Genzyme Corporation $294 15 payments
  7. BioCryst US Sales Co., LLC $253 9 payments
  8. Pfizer Inc. $157 8 payments
  9. Shire North American Group Inc $155 8 payments
  10. AbbVie, Inc. $154 8 payments
  11. Other $986 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $4,948 221 payments
Products named General payments · program years 2019–2022
  1. CUTAQUIG $833 14 payments
  2. DUPIXENT Inflammation And Immunology $682 28 payments
  3. DUPIXENT Immunology $436 22 payments
  4. CUVITRU $326 13 payments
  5. HYQVIA $253 11 payments
  6. Orladeyo $253 9 payments
  7. DUPIXENT Immunology $212 11 payments
  8. TRELEGY ELLIPTA $211 17 payments
  9. TEZSPIRE $168 8 payments
  10. RINVOQ $158 8 payments
  11. Other $1,915 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record